Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

308 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Retreatment with interferon and ribavirin vs interferon alone according to viraemia in interferon responder-relapser hepatitis C patients: a prospective multicentre randomized controlled study.
Portal I, Bourlière M, Halfon P, De Lédinghen V, Couzigou P, Bernard PH, Blanc F, Caroli-Bosc F, Arpurt JP, Vetter D, Mathieu-Chandelier C, Chazouillères O, Thiefin G, Pol S, Sogni P, Abergel A, Bailly F, Picon M, Debonne JM, Zamora C, Alleman I, Moreau X, Doll F, Eugène C, Ducloux S, Larrey D, Ouzan D, Grimaud JC, Gouvernet J, Botti G, Gérolami V, Khiri H, Gérolami A, Gauthier AP, Botta-Fridlund D. Portal I, et al. Among authors: abergel a. J Viral Hepat. 2003 May;10(3):215-23. doi: 10.1046/j.1365-2893.2003.00426.x. J Viral Hepat. 2003. PMID: 12753341 Clinical Trial.
Tenoxicam, a non-steroid anti-inflammatory drug, is unable to increase the response rate in patients with chronic hepatitis C treated by alpha interferon.
Zarski JP, Maynard-Muet M, Chousterman S, Baud M, Barnoud R, Abergel A, Bacq Y, Combis JM, Causse X, Tran A, Oberti F, Minello A, Bresson-Hadni S, Bailly F, Raabe JJ, Leroy V, Hamici L, Hicham T, Girardin MF. Zarski JP, et al. Among authors: abergel a. Hepatology. 1998 Mar;27(3):862-7. doi: 10.1002/hep.510270332. Hepatology. 1998. PMID: 9500719 Clinical Trial.
A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, France.
Pol S, Couzigou P, Bourlière M, Abergel A, Combis JM, Larrey D, Tran A, Moussalli J, Poupon R, Berthelot P, Bréchot C. Pol S, et al. Among authors: abergel a. J Hepatol. 1999 Jul;31(1):1-7. doi: 10.1016/s0168-8278(99)80157-3. J Hepatol. 1999. PMID: 10424277 Clinical Trial.
Lack of effect of propranolol in the prevention of large oesophageal varices in patients with cirrhosis: a randomized trial. French-Speaking Club for the Study of Portal Hypertension.
Calés P, Oberti F, Payen JL, Naveau S, Guyader D, Blanc P, Abergel A, Bichard P, Raymond JM, Canva-Delcambre V, Vetter D, Valla D, Beauchant M, Hadengue A, Champigneulle B, Pascal JP, Poynard T, Lebrec D. Calés P, et al. Among authors: abergel a. Eur J Gastroenterol Hepatol. 1999 Jul;11(7):741-5. doi: 10.1097/00042737-199907000-00011. Eur J Gastroenterol Hepatol. 1999. PMID: 10445794 Clinical Trial.
[Hepavir, the first observational study of one cohort of patients treated with alpha-2a interferon, monotherapy. Evaluation of asthenia and its social consequences].
Roudot-Thoraval F, Abergel A, Allaert F, Bourlière M, Desmorat H, Fagnani F, Fontanges T, Hanana A, Pol S, Zarski JP, Rousseaux C, Gandossi C, Samelson L, Dole S, Dantin S, Eberlé F, Saint-Marc-Girardin MF; Groupe d'Etude Pour Hépavir. Roudot-Thoraval F, et al. Among authors: abergel a. Gastroenterol Clin Biol. 2001 Dec;25(12):1061-6. Gastroenterol Clin Biol. 2001. PMID: 11910986 Free article. French.
The antibody response to hepatitis B virus vaccination is negatively influenced by the hepatitis C virus viral load in patients with chronic hepatitis C: a case-control study.
Leroy V, Bourliere M, Durand M, Abergel A, Tran A, Baud M, Botta-Fridlund D, Gerolami A, Ouzan D, Halfon P, Zarski JP. Leroy V, et al. Among authors: abergel a. Eur J Gastroenterol Hepatol. 2002 May;14(5):485-9. doi: 10.1097/00042737-200205000-00004. Eur J Gastroenterol Hepatol. 2002. PMID: 11984145 Clinical Trial.
Daily or three times per week interferon alpha-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone.
de Lédinghen V, Trimoulet P, Winnock M, Bernard PH, Bourlière M, Portal I, Rémy AJ, Szostak N, Lévy S, Tran A, Abergel A, Chêne G, Fleury H, Couzigou P; French Multicenter Study Group. de Lédinghen V, et al. Among authors: abergel a. J Hepatol. 2002 Jun;36(6):819-26. doi: 10.1016/s0168-8278(02)00071-5. J Hepatol. 2002. PMID: 12044534 Clinical Trial.
Antiviral effect of ribavirin in early non-responders to interferon monotherapy assessed by kinetics of hepatitis C virus RNA and hepatitis C virus core antigen.
Lunel F, Veillon P, Fouchard-Hubert I, Loustaud-Ratti V, Abergel A, Silvain C, Rifflet H, Blanchi A, Causse X, Bacq Y, Payan C; Fontevraud Study Group. Lunel F, et al. Among authors: abergel a. J Hepatol. 2003 Nov;39(5):826-33. doi: 10.1016/s0168-8278(03)00402-1. J Hepatol. 2003. PMID: 14568267 Clinical Trial.
Histological response in patients treated by interferon plus ribavirin for hepatitis C virus-related severe fibrosis.
Abergel A, Darcha C, Chevallier M, Ughetto S, Henquell C, Pol S, de Ledinghen V, Canva V, Bronowicki JP, Tran A, Martineau N, Lafeuille H, Dechelotte P, Bommelaer G, Bonny C; French Multicentre Study Group. Abergel A, et al. Eur J Gastroenterol Hepatol. 2004 Nov;16(11):1219-27. doi: 10.1097/00042737-200411000-00022. Eur J Gastroenterol Hepatol. 2004. PMID: 15489585 Clinical Trial.
308 results